1-17 of 17
Christopher J. Lord
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR010: CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality

Jean C. Tien, Yu Chang, Yuping Zhang, Jonathan Chou, Yunhui Cheng, Xiaoju Wang, Jianzhang Yang, Rahul Mannan, Palak Shah, Xiao-Ming Wang, Abbey Todd, Sanjana Eyunni, Caleb Cheng, Xuhong Cao, Yi Bao, James Neiswender, Rachel Brough, Stephen Pettitt, Estefania Labanca, Yuzhuo Wang, Marcin Cieslik, Christopher J. Lord, Ke Ding, Arul M. Chinnaiyan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (6_Supplement): PR010.
https://doi.org/10.1158/1538-8514.SYNTHLETH24-PR010
Published: 10 June 2024
View article titled, Abstract PR010: <em>CDK12</em> loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality
Journal Articles

Abstract B020: SF3B1 hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response

Philip Bland, Harry Saville, Patty T Wai, Lucinda Curnow, Jadwiga Nieminuszczy, Nivedita Ravindran, Holly E Barker, James Wright, Lu Yu, Ioanna Mavrommati, Barrie Peck, Patrycja Gazinska, Helen N Pemberton, Aditi Gulati, Naomi Guppy, Ioannis Roxanis, Guy Pratt, Ceri Oldreive, Tatjana Stankovic, Samantha Barlow, Helen Kalirai, Sarah E Coupland, Ronan Broderick, Samar Alsafadi, Alexandre Houy, Marc-Henri Stern, Stephen Pettit, Jyoti S Choudhary, Syed Haider, Wojciech Niedzwiedz, Christopher J Lord, Rachael Natrajan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B020.
https://doi.org/10.1158/1535-7163.TARG-23-B020
Published: 01 December 2023
View article titled, Abstract B020: <em>SF3B1 </em>hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response
Journal Articles

Abstract P080: Analysis of clinical BRCA1/2 reversions identifies hotspot mutations and predicted neoantigens associated with therapy resistance

Stephen J. Pettitt, Jessica Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Syed Haider, Andre N. J. Tutt, Christopher J. Lord
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P080.
https://doi.org/10.1158/1535-7163.TARG-21-P080
Published: 01 December 2021
View article titled, Abstract P080: Analysis of clinical <em>BRCA1/2</em> reversions identifies hotspot mutations and predicted neoantigens associated with therapy resistance
Journal Articles

Abstract P056: Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

Diana A. Zatreanu, Helen M. R. Robinson, Omar Alkhatib, Marie Boursier, Harry Finch, Lerin Geo, Diego Grande, Vera Grinkevich, Robert Heald, Sophie Langdon, Jayesh Majithiya, Claire McWhirter, Niall M. B. Martin, Shaun Moore, Joana Neves, Eeson Rajendra, Marco Ranzani, Theresia Schaedler, Martin Stockley, Kimberley Wiggins, Rachel Brough, Sandhya Sridhar, Aditi Gulati, Nan Shao, Luned M Badder, Daniela Novo, Eleanor G. Knight, Rebecca Marlow, Syed Haider, Elsa Callen, Graeme Hewitt, Joost Schimmel, Remko Prevo, Christina Alli, Amanda Ferdinand, Cameron Bell, Peter Blencowe, Mathew Calder, Mark Charles, Jayne Curry, Tennyson Ekwuru, Katherine Ewings, Andre Nussenzweig, Marcel Tijsterman, Andrew Tutt, Simon J. Boulton, Geoff S. Higgins, Steve Pettitt, Graeme C. M. Smith, Christopher J. Lord
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P056.
https://doi.org/10.1158/1535-7163.TARG-21-P056
Published: 01 December 2021
View article titled, Abstract P056: Polθ inhibitors elicit <em>BRCA</em>-gene synthetic lethality and target PARP inhibitor resistance
Journal Articles

Abstract P057: The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin

Dragomir Krastev, Shudong Li, Yilun Sun, Yves Pommier, Kristijan Ramadan, Christopher J. Lord
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P057.
https://doi.org/10.1158/1535-7163.TARG-21-P057
Published: 01 December 2021
View article titled, Abstract P057: The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin
Journal Articles

A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics

Jelmar Quist, Hasan Mirza, Maggie C.U. Cheang, Melinda L. Telli, Joyce A. O'Shaughnessy, Christopher J. Lord, Andrew N.J. Tutt, Anita Grigoriadis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (1): 204–212.
https://doi.org/10.1158/1535-7163.MCT-18-0243
Published: 02 January 2019
View article titled, A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Open the PDF for A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics in another window
Includes: Supplementary data
Journal Articles

Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer

Kalnisha Naidoo, Patty T. Wai, Sarah L. Maguire, Frances Daley, Syed Haider, Divya Kriplani, James Campbell, Hasan Mirza, Anita Grigoriadis, Andrew Tutt, Paul M. Moseley, Tarek M.A. Abdel-Fatah, Stephen Y.T. Chan, Srinivasan Madhusudan, Emad A. Rhaka, Ian O. Ellis, Christopher J. Lord, Yinyin Yuan, Andrew R. Green, Rachael Natrajan
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (1): 306–315.
https://doi.org/10.1158/1535-7163.MCT-17-0760
Published: 01 January 2018
View article titled, Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer
Open the PDF for Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

Amy Dréan, Chris T. Williamson, Rachel Brough, Inger Brandsma, Malini Menon, Asha Konde, Isaac Garcia-Murillas, Helen N. Pemberton, Jessica Frankum, Rumana Rafiq, Nicholas Badham, James Campbell, Aditi Gulati, Nicholas C. Turner, Stephen J. Pettitt, Alan Ashworth, Christopher J. Lord
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (9): 2022–2034.
https://doi.org/10.1158/1535-7163.MCT-17-0098
Published: 04 September 2017
View article titled, Modeling Therapy Resistance in <em>BRCA1/2</em>-Mutant Cancers
Open the PDF for Modeling Therapy Resistance in <em>BRCA1/2</em>-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson, Simon McDade, James Campbell, Asha Kigozi, Rumana Rafiq, Helen Pemberton, Rachel Natrajan, Josephine Joel, Holly Astley, Claire Mahoney, Jonathan D. Moore, Chris Torrance, John D. Gordan, James T. Webber, Rebecca S. Levin, Kevan M. Shokat, Sourav Bandyopadhyay, Christopher J. Lord, Alan Ashworth
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (7): 1472–1484.
https://doi.org/10.1158/1535-7163.MCT-15-0554
Published: 05 July 2016
View article titled, Synthetic Lethal Targeting of <em>ARID1A</em>-Mutant Ovarian Clear Cell Tumors with Dasatinib
Open the PDF for Synthetic Lethal Targeting of <em>ARID1A</em>-Mutant Ovarian Clear Cell Tumors with Dasatinib in another window
Includes: Supplementary data
Journal Articles

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Yeon-Jin Kwon, Kevin Petrie, Boris A. Leibovitch, Lei Zeng, Mihaly Mezei, Louise Howell, Veronica Gil, Rossitza Christova, Nidhi Bansal, Shuai Yang, Rajal Sharma, Edgardo V. Ariztia, Jessica Frankum, Rachel Brough, Yordan Sbirkov, Alan Ashworth, Christopher J. Lord, Arthur Zelent, Eduardo Farias, Ming-Ming Zhou, Samuel Waxman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (8): 1824–1836.
https://doi.org/10.1158/1535-7163.MCT-14-0980-T
Published: 05 August 2015
View article titled, Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Open the PDF for Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways

Marieke Aarts, Ilirjana Bajrami, Maria T. Herrera-Abreu, Richard Elliott, Rachel Brough, Alan Ashworth, Christopher J. Lord, Nicholas C. Turner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (4): 865–876.
https://doi.org/10.1158/1535-7163.MCT-14-0845
Published: 09 April 2015
View article titled, Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways
Open the PDF for Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways in another window
Includes: Supplementary data
Journal Articles

Abstract A36: A transposon-based genetic screen in haploid mouse embryonic stem cells identifies Parp1 as a major mediator of olaparib toxicity

Stephen J. Pettitt, Farah L. Rehman, Ilirjana Bajrami, Helen Pemberton, Rachel Brough, Iwanka Kozarewa, Christopher J. Lord, Alan Ashworth
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): A36.
https://doi.org/10.1158/1535-7163.PMS-A36
Published: 01 May 2014
View article titled, Abstract A36: A transposon-based genetic screen in haploid mouse embryonic stem cells identifies Parp1 as a major mediator of olaparib toxicity
Journal Articles

Abstract A09: Induced aggravation of oxidative DNA damage as a targeted synthetic lethal approach in mismatch repair-deficient tumors

Yari Fontebasso, Christopher J. Lord, Alan Ashworth
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): A09.
https://doi.org/10.1158/1535-7163.PMS-A09
Published: 01 May 2014
View article titled, Abstract A09: Induced aggravation of oxidative DNA damage as a targeted synthetic lethal approach in mismatch repair-deficient tumors
Journal Articles

Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase

Todd R. Mereniuk, Mohamed A.M. El Gendy, Ana M. Mendes-Pereira, Christopher J. Lord, Sunita Ghosh, Edan Foley, Alan Ashworth, Michael Weinfeld
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (10): 2135–2144.
https://doi.org/10.1158/1535-7163.MCT-12-1093
Published: 07 October 2013
View article titled, Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase
Open the PDF for Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase in another window
Includes: Supplementary data
Journal Articles

Abstract B201: Identification of miRNA modulators to PARP inhibitor response.

Sari Neijenhuis, Ilirjana Bajrami, James Campbell, Christopher J. Lord, Alan Ashworth
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B201.
https://doi.org/10.1158/1535-7163.TARG-11-B201
Published: 12 November 2011
View article titled, Abstract B201: Identification of miRNA modulators to PARP inhibitor response.
Journal Articles

Abstract A239: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells

Teeara Rawjee, Martin Rowlands, Craig McAndrew, Mark Stubbs, Christopher J. Lord, Jorge S. Reis‐Filho, Alan Ashworth, Wynne Aherne, Paul Workman, Julian Blagg, Spyridon Linardopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A239.
https://doi.org/10.1158/1535-7163.TARG-09-A239
Published: 10 December 2009
View article titled, Abstract A239: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells
Journal Articles

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment

Benjamin J. Friedmann, Martyn Caplin, Boris Savic, Tahir Shah, Christopher J. Lord, Alan Ashworth, John A. Hartley, Daniel Hochhauser
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (2): 209–218.
https://doi.org/10.1158/1535-7163.MCT-05-0239
Published: 27 February 2006
View article titled, Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment
Open the PDF for Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment in another window